OPTN News and Press, OptiNose Inc. From 03/06/19

OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call March 6, 2019 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations and Business Operations Peter Miller - Chief Executive Officer Keith Goldan - Chief Financial Officer Tom Gibbs - Chief Comme...

The following slide deck was published by OptiNose, Inc. in conjunction with their 2018 Q4 earnings Read more ...

OptiNose (NASDAQ: OPTN ): Q4 GAAP EPS of -$0.64 beats by $0.21 . More news on: OptiNose, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 06, 2019 (GLOBE NEWSW...

YARDLEY, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter 2018, before market open ...

YARDLEY, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the United States Patent and Trademark Office (USPTO) recently issued four patents covering...

YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic outcomes data at the 2019 American Ac...

Optinose (NASDAQ: OPTN ) inks a license agreemen t with Inexia granting the latter certain rights to its Exhalation Delivery Systems (EDS) technology and other intellectual property for use in discovering and developing new therapies based on positive modulators of Orexin OX1 and OX2 for ne...

YARDLEY, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a license ag...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f...